| DESCRIPTION | - ARBER et al., Blood, (20160519), vol. 127, no. 20 | - |
| DESCRIPTION | - Blood, (20150000), vol. 126, no. 3, pages 291 - 299 | - |
| DESCRIPTION | - GREENBERG et al., Blood, (20120920), vol. 120, no. 12, pages 2454 - 2465 | - |
| DESCRIPTION | - HU; SMYTH, ELDA: Journal of Immunological Methods, (20090000), vol. 347, pages 70 - 78 | - |
| DESCRIPTION | - MCEARCHERN et al., Clin Cancer Res, (20080000), vol. 14, no. 23, page 7763 | - |
| DESCRIPTION | - POLLYEA; JORDAN, Blood, (20170000), vol. 129, pages 1627 - 1635 | - |
| DESCRIPTION | - RIETHER et al., J Exp Med., (20170200), vol. 214, no. 2, pages 359 - 380 | - |
| DESCRIPTION | - RIETHER et al., J. Exp. Med., (20170200), vol. 214, no. 2, pages 359 - 380 | - |
| DESCRIPTION | - SILENCE et al., MAbs, (20140300), vol. 6, no. 2, pages 523 - 32 | - |
| EXAMINATION | - CARSTEN RIETHER ET AL, "CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia", JOURNAL OF EXPERIMENTAL MEDICINE, US, (20161228), vol. 214, no. 2, doi:10.1084/jem.20152008, ISSN 0022-1007, pages 359 - 380, XP055735891 | |
| EXAMINATION | - MAY KUNG SUTHERLAND ET AL, "5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia", MABS LANDES BIOSCIENCE, (20100701), vol. 24, doi:10.4161/mabs.12203, pages 440 - 448, XP055096014 | |
| INTERNATIONAL-SEARCH-REPORT | - DEMPKE WOLFRAM C M ET AL, "Second- and third-generation drugs for immuno-oncology treatment-The more the better?", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM, NL, (20170210), vol. 74, doi:10.1016/J.EJCA.2017.01.001, ISSN 0959-8049, pages 55 - 72, XP029933747 [A] 1-52 * paragraph [05.6] * | |
| INTERNATIONAL-SEARCH-REPORT | - J. JACOBS ET AL, "CD70: An emerging target in cancer immunotherapy", PHARMACOLOGY AND THERAPEUTICS., GB, (201511), vol. 155, doi:10.1016/j.pharmthera.2015.07.007, ISSN 0163-7258, pages 1 - 10, XP055289894 [A] 1-52 * See §4 "Targeting CD70" * | |
| OPPOSITION | - Anonymous, "arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers", argenx, argenx, URL: https://argenx.com/news/2015/argen-x-and-university-bern-enter-license-agreement-develop-argx-110-based-combination, XP093246340 | - |
| OPPOSITION | - Anonymous, " argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine", argenx, argenx, URL: https://us.argenx.com/news/2016/argenx-announces-publication-seminal-data-supporting-therapeutic-potential-argx-110-acute, XP093246346 | - |
| OPPOSITION | - Anonymous, "argenx launches Phase I/II study of ARGX110 in combination with azacitidine in newly diagnosed AML patients", argenx, argenx, URL: https://us.argenx.com/news/2016/argenx-launches-phase-iii-study-argx-110-combination-azacitidine-newly-diagnosed-aml-patients, XP093246321 | - |
| OPPOSITION | - Anonymous, "arGEN-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Model", argenx, argenx, URL: https://us.argenx.com/news/2014/argen-x-reports-preclinical-data-argx-110-chronic-myelogenous-leukemia-model, XP093246336 | - |
| OPPOSITION | - Anonymous, " argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting", Argenx, Argenx, URL: https://us.argenx.com/news/2017/argenx-provide-updates-phase-12-clinical-trials-argx-110-acute-myeloid-leukemia-and-cutaneous, XP093246331 | - |
| OPPOSITION | - Anonymous, "ARGX-110, a novel anti-CD70 antibody, meets translational development goals in dose escalation part of Phase lb cancer study", argenx, argenx, URL: https://us.argenx.com/news/2013/argx-110-novel-anti-cd70-antibody-meets-translational-development-goals-dose-escalation-part, XP093246334 | - |
| OPPOSITION | - Anonymous, "A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)", ClinicalTrials.gov; NCT03030612, ClinicalTrials.gov; NCT03030612, URL: https://clinicaltrials.gov/study/NCT03030612?term=NCT03030612&rank=1&a=2, XP093246308 | - |
| OPPOSITION | - Anonymous, "A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)", ClinicalTrials.gov; NCT03030612, ClinicalTrials.gov; NCT03030612, URL: https://clinicaltrials.gov/study/NCT03030612?term=NCT03030612&rank=1&a=4, XP093246328 | - |
| OPPOSITION | - D25 - T2506_12 | - |
| OPPOSITION | - Klepin Heidi D., "Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly", CLINICS IN GERIATRIC MEDICINE., W.B. SOUNDERS CO., LONDON., GB, GB , (20160201), vol. 32, no. 1, doi:10.1016/j.cger.2015.08.010, ISSN 0749-0690, pages 155 - 173, XP093246315 | |
| OPPOSITION | - Aggarwal, S. ; He, T. ; FitzHugh, W. ; Rosenthal, K. ; Feild, B. ; Heidbrink, J. ; Mesmer, D. ; Ruben, S.M. ; Moore, P.A., "Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer", GYNECOLOGIC ONCOLOGY., ACADEMIC PRESS, LONDON., GB, GB , (20091201), vol. 115, no. 3, doi:10.1016/j.ygyno.2009.08.031, ISSN 0090-8258, pages 430 - 437, XP026733157 | |
| OPPOSITION | - Schönefeldt C, Sockel K, Wehner R, Sopper S, Wolf D, Wermke M, Thiede C, Oelschlägel U, Ehninger G, Bornhäuser M, Platzbecker U, Schmitz M, "Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation", Blood Cancer Journal, Nature Publishing Group, GB, GB , vol. 3, no. 8, doi:10.1038/bcj.2013.35, ISSN 2044-5385, pages e136 - e136, XP093271812 | |
| OPPOSITION | - Riether Carsten; Pabst Thomas; Höpner Sabine; Bacher Ulrike; Hinterbrandner Magdalena; Banz Yara; Müller Rouven; Manz Markus G.; Gharib Walid H.; Francisco David; Bruggmann Remy; van Rompaey Luc; Moshir Mahan; Delahaye Tim; Gandini Domenica; Erzeel Ellen; Hultberg Anna; Fung Samson; de Haard Hans; Leupin Nicolas; Ochsenbein Adrian F., "Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents", Nature Medicine(Author manuscript ), Nature Publishing Group US, New York, New York, (20200629), vol. 26, no. 9, doi:10.1038/s41591-020-0910-8, ISSN 1078-8956, pages 1459 - 1467, XP037241569 | |
| OPPOSITION | - Carsten Riether, Christian M. Schürch, Elias D. Bührer, Magdalena Hinterbrandner, Anne-Laure Huguenin, Sabine Hoepner, Inti Zlobec, Thomas Pabst, Ramin Radpour, Adrian F. Ochsenbein, "CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia", Journal of Experimental Medicine, Rockefeller University Press, US, US , (20170201), vol. 214, no. 2, doi:10.1084/jem.20152008, ISSN 0022-1007, pages 359 - 380, XP055735891 | |
| OPPOSITION | - Bas Kersten; Matthijs Valkering; Rolf Wouters; Rosa Amerongen; Diana Hanekamp; Zinia Kwidama; Peter Valk; Gert Ossenkoppele; Wendelien Zeijlemaker; Gertjan Kaspers; Jacqueline Cloos; Gerrit J. Schuurhuis, "CD45RA, a specific marker for leukaemia stem cell sub‐populations in acute myeloid leukaemia", British Journal of Haematology, John Wiley, Hoboken, USA, Hoboken, USA, (20160127), vol. 173, no. 2, doi:10.1111/bjh.13941, ISSN 0007-1048, pages 219 - 235, XP071121862 | |
| OPPOSITION | - Riether Carsten, Schürch Christian M., Flury Christoph, Hinterbrandner Magdalena, Drück Linda, Huguenin Anne-Laure, Baerlocher Gabriela M., Radpour Ramin, Ochsenbein Adrian F., "Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling", SCIENCE TRANSLATIONAL MEDICINE, American Association for the Advancement of Science, (20150729), vol. 7, no. 298, doi:10.1126/scitranslmed.aab1740, ISSN 1946-6234, XP093246350 | |
| OPPOSITION | - Stübig Thomas, Badbaran Anita, Luetkens Tim, Hildebrandt York, Atanackovic Djordje, Binder Thomas M. C., Fehse Boris, Kröger Nicolaus, "5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity", MEDIATORS OF INFLAMMATION., RAPID COMMUNICATION OF OXFORD LTD., OXFORD., GB, GB , (20140101), vol. 2014, doi:10.1155/2014/418292, ISSN 0962-9351, pages 1 - 12, XP093184980 | |
| OPPOSITION | - Kaminskas Edvardas, Farrell Ann, Abraham Sophia, Baird Amy, Hsieh Li-Shan, Lee Shwu-Luan, Leighton John K., Patel Hasmukh, Rahman Atiqur, Sridhara Rajeshwara, Wang Yong-Cheng, Pazdur Richard, "Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes", Clinical Cancer Research, Association for Cancer Research, US, US, (20050515), vol. 11, no. 10, doi:10.1158/1078-0432.CCR-04-2135, ISSN 1078-0432, pages 3604 - 3608, XP093026273 | |
| OPPOSITION | - MCEARCHERN JULIE A ET AL, "Preclinical characterization of SGN-70, a humanized antibody directed against CD70.", Clinical Cancer Research, Association for Cancer Research, US, US, (20081201), vol. 14, no. 23, doi:10.1158/1078-0432.CCR-08-0493, ISSN 1078-0432, pages 7763 - 7772, XP002556891 | |
| OPPOSITION | - Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Marie Maerevoet, Jean-Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, Jean-Marie Michot, Karen Silence, Anna Hultberg, Domenica Gandini, Hans De Haard, Vincent Ribrag, Marc Peeters, Alain Thibault, Nicolas Leupin, Ahmad Awada, "Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies", Clinical Cancer Research, Association for Cancer Research, US, US, (20171101), vol. 23, no. 21, doi:10.1158/1078-0432.CCR-17-0613, ISSN 1078-0432, pages 6411 - 6420, XP055584259 | |
| OPPOSITION | - Dombret Hervé, Seymour John F., Butrym Aleksandra, Wierzbowska Agnieszka, Selleslag Dominik, Jang Jun Ho, Kumar Rajat, Cavenagh James, Schuh Andre C., Candoni Anna, Récher Christian, Sandhu Irwindeep, Bernal Del Castillo Teresa, Al-Ali Haifa Kathrin, Martinelli Giovanni, Falantes Jose, Noppeney Richard, Stone Richard M., Minden Mark D., Mcintyre Heidi, Songer Steve, Lucy Lela M., Beach C. L., Döhner Hartmut, "International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts", Blood, W.B. Saunders, (20150716), vol. 126, no. 3, doi:10.1182/blood-2015-01-621664, ISSN 0006-4971, pages 291 - 299, XP093246319 | |
| OPPOSITION | - Riether Carsten; Schürch Christian M.; Radpour Ramin; Hinterbrandner Magdalena; Huguenin Anne-Laure; Ochsenbein Adrian F., "CD70/CD27 Signaling Mediates Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors By Compensatory Activation of the Wnt Pathway", Blood, W.B. Saunders, (20141114), vol. 124, no. 21, doi:10.1182/blood.V124.21.400.400, ISSN 0006-4971, page 400, XP086741704 | |
| OPPOSITION | - Hinterbrandner Magdalena; Kallen Nils Maria; Lüthi Ursina; Pabst Thomas; Van Rompaey Luc; Leupin Nicolas; De Haard Hans; Ochsenbein Adrian F; Riether Carsten, "Blocking CD70/CD27 Signaling in Combination with Hypomethylating Agents Eradicates Human CD34+ AML Stem and Progenitor Cells in Vitro and In Vivo", Blood, W.B. Saunders, (20171208), vol. 130, doi:10.1182/blood.V130.Suppl_1.2652.2652, ISSN 0006-4971, page 2652, XP086631541 | |
| OPPOSITION | - Michot Jean-Marie, Maerevoet Marie, Aftimos Philippe Georges, Rottey Sylvie, Rolfo Christian Diego, Offner Fritz, Van Rompaey Luc, Moshir Mahan, De Haard Hans, Silence Karen, Pauwels Patrick, Zwaenepoel Karen, Awada Ahmad, Bron Dominique, Ribrag Vincent, "Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110.", Journal of Clinical Oncology, Grune & Stratton, (20160520), vol. 34, no. 15_suppl, doi:10.1200/JCO.2016.34.15_suppl.7556, ISSN 0732-183X, pages 7556 - 7556, XP093184915 | |
| OPPOSITION | - Liu, Sheng, Liu, Yu, Zhang, "Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas", ONCOTARGETS AND THERAPY, Dove Medical Press, doi:10.2147/OTT.S44445, ISSN 1178-6930, page 615, XP093246355 | |
| OPPOSITION | - Shultz Leonard D; Lyons Bonnie L; Burzenski Lisa M; Gott Bruce; Chen Xiaohua; Chaleff Stanley; Kotb Malak; Gillies Stephen D; King Marie; Mangada Julie; Greiner Dale L; Handgretinger Rupert, "Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma(null) mice engrafted with mobilized human hemopoietic stem cells", Journal of Immunology, Williams & Wilkins Co., (20050515), vol. 174, no. 10, doi:10.4049/jimmunol.174.10.6477, ISSN 0022-1767, pages 6477 - 6489, XP008164911 | |
| OPPOSITION | - Karen Silence, Torsten Dreier, Mahan Moshir, Peter Ulrichts, Sofie Me Gabriels, Michael Saunders, Harald Wajant, Peter Brouckaert, Leander Huyghe, Tim Van Hauwermeiren, Alain Thibault, Hans J De Haard, "ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade", mAbs, Landes Bioscience, US, US , (20140301), vol. 6, no. 2, doi:10.4161/mabs.27398, ISSN 1942-0870, pages 523 - 532, XP055245046 | |
| SEARCH | [ ] - D1 - Clinical Trials ID NCT03030612, v2 15.05.2017 | - |
